Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Ensuring Patient Access to Critical Breakthrough Products Act
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Transitional Coverage for Emerging Technologies (TCET)/MCIT Policies promoting medical innovation Heart Valve Disease Awareness AI in Healthcare FDA Reauthorization/FDA User Fees Diversity in Clinical Trials Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
EDWARDS LIFESCIENCES LLC via EDWARDS LIFESCIENCES, LLC
2026 · third_quarter · Q3
CMS Coverage Policies For Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes RAPID) Heart Valve Disease Awareness National Coverage Determination for TAVR Clinical Trials Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) Regulatory Alignment for Predictable and Immediate Device coverage pathway Policies promoting medical innovation Heart Valve Disease Awareness AI in Healthcare FDA Reauthorization/FDA User Fees Diversity in Clinical Trials Coverage with Evidence Development
Source: Senate LDA
Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Transitional Coverage for Emerging Technologies (TCET)/MCIT Policies promoting medical innovation Heart Valve Disease Awareness AI in Healthcare FDA Reauthorization/FDA User Fees Diversity in Clinical Trials (Health Equity Issues) Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies For Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Heart Valve Disease Awareness Transcatheter Mitral Valve National Coverage Decision National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials (Health Equity Issues) Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies For Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) Regulatory Alignment for Predictable and Immediate Device coverage pathway Policies promoting medical innovation Heart Valve Disease Awareness AI in Healthcare FDA Reauthorization/FDA User Fees Diversity in Clinical Trials Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies For Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes RAPID) Heart Valve Disease Awareness National Coverage Determination for TAVR Clinical Trials Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Transitional Coverage for Emerging Technologies (TCET)/MCIT Policies promoting medical innovation Heart Valve Disease Awareness AI in Healthcare FDA Reauthorization/FDA User Fees Diversity in Clinical Trials (Health Equity Issues) Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Transitional Coverage for Emerging Technologies (TCET)/MCIT Policies promoting medical innovation Heart Valve Disease Awareness AI in Healthcare FDA Reauthorization/FDA User Fees Diversity in Clinical Trials Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies For Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes RAPID) Heart Valve Disease Awareness National Coverage Determination for TAVR Clinical Trials Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) Regulatory Alignment for Predictable and Immediate Device coverage pathway Policies promoting medical innovation Heart Valve Disease Awareness AI in Healthcare FDA Reauthorization/FDA User Fees Diversity in Clinical Trials Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies For Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies For Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Heart Valve Disease Awareness Transcatheter Mitral Valve National Coverage Decision National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials (Health Equity Issues) Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization/FDA User Fees Diversity in Clinical Trials
Ensuring Patient Access to Critical Breakthrough Products Act
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization/FDA User Fees Diversity in Clinical Trials
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Ensuring Patient Access to Critical Breakthrough Products (S.1717) Transitional Coverage for Emerging Technologies (TCET) Guidance Policies promoting medical innovation Heart Valve Disease Awareness AI in Healthcare FDA Reauthorization for 2022/FDA User Fees Diversity in Clinical Trials Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization/FDA User Fees Diversity in Clinical Trials
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (s.1717) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization/FDA User Fees Diversity in Clinical Trials
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691/S.5349) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Ensuring Patient Access to Critical Breakthrough Products (H.R.1691 S.5349) Transitional Coverage for Emerging Technologies (TCET) Guidance Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization for 2022/FDA User Fees Diversity in Clinical Trials Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Ensuring Patient Access to Critical Breakthrough Products (H.R.1691 S.5349) Transitional Coverage for Emerging Technologies (TCET) Guidance Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization for 2022/FDA User Fees Diversity in Clinical Trials Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691/S.5349) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691/S.5349) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Health Equity Issues Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Health Equity Issues Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.1691) Transitional Coverage for Emerging Technologies (TCET) guidance Policies promoting medical innovation Heart Valve Disease Awareness Cybersecurity for Healthcare Industry AI in Healthcare FDA Reauthorization for 2022/FDA User Fees Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act (includes CURES 2.1 proposal) Shortage Reporting Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Health Equity Issues Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.1691/S.5439) Transitional Coverage for Emerging Technologies (TCET) guidance Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization for 2022/FDA User Fees Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act (includes CURES 2.1 proposal) Shortage Reporting Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691/S.5349) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Health Equity Issues Coverage with Evidence Development
Drought Resilient Infrastructure Act of 2024
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.1691/S.5439) Transitional Coverage for Emerging Technologies (TCET) guidance Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization for 2022/FDA User Fees Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act (includes CURES 2.1 proposal) Shortage Reporting Coverage with Evidence Development
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.1691/S.5439) Transitional Coverage for Emerging Technologies (TCET) guidance Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization for 2022/FDA User Fees Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act (includes CURES 2.1 proposal) Shortage Reporting Coverage with Evidence Development
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.1691) Transitional Coverage for Emerging Technologies (TCET) guidance Policies promoting medical innovation Heart Valve Disease Awareness Cybersecurity for Healthcare Industry AI in Healthcare FDA Reauthorization for 2022/FDA User Fees Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act (includes CURES 2.1 proposal) Shortage Reporting Coverage with Evidence Development
Financial Literacy to Financial Freedom Act
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.1961) Transitional Coverage for Emerging Technologies (TCET) guidance Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Health Equity Issues (Diversity in Clinical Trials) H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Shortage Reporting Coverage with Evidence Development
Southern Utah Open OHV Areas Act
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.1961) Transitional Coverage for Emerging Technologies (TCET) guidance Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Health Equity Issues (Diversity in Clinical Trials) H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Shortage Reporting Coverage with Evidence Development
Tariffs
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
EDWARDS LIFESCIENCES LLC via EDWARDS LIFESCIENCES, LLC
2026 · second_quarter · Q2
Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Transitional Coverage for Emerging Technologies (TCET)/MCIT Policies promoting medical innovation Heart Valve Disease Awareness AI in Healthcare FDA Reauthorization/FDA User Fees Diversity in Clinical Trials Coverage with Evidence Development
CMS Coverage Policies For Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Coverage with Evidence Development
Tariffs
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
EDWARDS LIFESCIENCES LLC via EDWARDS LIFESCIENCES, LLC
2026 · first_quarter · Q1
Tariffs
CMS Coverage Policies For Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Heart Valve Disease Awareness Transcatheter Mitral Valve National Coverage Decision National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials (Health Equity Issues) Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Transitional Coverage for Emerging Technologies (TCET)/MCIT Policies promoting medical innovation Heart Valve Disease Awareness AI in Healthcare FDA Reauthorization/FDA User Fees Diversity in Clinical Trials (Health Equity Issues) Coverage with Evidence Development
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
EDWARDS LIFESCIENCES LLC via EDWARDS LIFESCIENCES, LLC
2025 · fourth_quarter · Q4
Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization/FDA User Fees Diversity in Clinical Trials
CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development
Japan Reimbursement of Medical Devices
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
EDWARDS LIFESCIENCES LLC via EDWARDS LIFESCIENCES, LLC
2025 · third_quarter · Q3
Tariffs Japan Reimbursement of Medical Devices
Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization/FDA User Fees Diversity in Clinical Trials
CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
EDWARDS LIFESCIENCES LLC via EDWARDS LIFESCIENCES, LLC
2025 · second_quarter · Q2
Ensuring Patient Access to Critical Breakthrough Products (S.1717) Transitional Coverage for Emerging Technologies (TCET) Guidance Policies promoting medical innovation Heart Valve Disease Awareness AI in Healthcare FDA Reauthorization for 2022/FDA User Fees Diversity in Clinical Trials Coverage with Evidence Development
CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (s.1717) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development
EDWARDS LIFESCIENCES LLC via EDWARDS LIFESCIENCES, LLC
2025 · first_quarter · Q1
Ensuring Patient Access to Critical Breakthrough Products (H.R.1691 S.5349) Transitional Coverage for Emerging Technologies (TCET) Guidance Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization for 2022/FDA User Fees Diversity in Clinical Trials Coverage with Evidence Development
CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691/S.5349) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development
EDWARDS LIFESCIENCES LLC via EDWARDS LIFESCIENCES, LLC
2024 · fourth_quarter · Q4
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691/S.5349) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Health Equity Issues Coverage with Evidence Development
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.1691/S.5439) Transitional Coverage for Emerging Technologies (TCET) guidance Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization for 2022/FDA User Fees Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act (includes CURES 2.1 proposal) Shortage Reporting Coverage with Evidence Development
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
EDWARDS LIFESCIENCES LLC via EDWARDS LIFESCIENCES, LLC
2024 · third_quarter · Q3
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Health Equity Issues Coverage with Evidence Development
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.1691) Transitional Coverage for Emerging Technologies (TCET) guidance Policies promoting medical innovation Heart Valve Disease Awareness Cybersecurity for Healthcare Industry AI in Healthcare FDA Reauthorization for 2022/FDA User Fees Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act (includes CURES 2.1 proposal) Shortage Reporting Coverage with Evidence Development
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
EDWARDS LIFESCIENCES LLC via EDWARDS LIFESCIENCES, LLC
2024 · second_quarter · Q2
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.1961) Transitional Coverage for Emerging Technologies (TCET) guidance Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Health Equity Issues (Diversity in Clinical Trials) H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Shortage Reporting Coverage with Evidence Development
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Health Equity Issues Coverage with Evidence Development
Tariffs
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Tariffs
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE